成骨肉瘤发病机制为新靶点治疗开辟道路。
Osteosarcoma Pathogenesis Leads the Way to New Target Treatments.
机构信息
Medical Oncology Department, Hospital Santa Maria, Centro Hospitalar Universitário Lisboa Norte, 1600 Lisbon, Portugal.
Luís Costa Lab, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, 1600 Lisbon, Portugal.
出版信息
Int J Mol Sci. 2021 Jan 15;22(2):813. doi: 10.3390/ijms22020813.
Abstract
Osteosarcoma (OS) is a rare condition with very poor prognosis in a metastatic setting. Basic research has enabled a better understanding of OS pathogenesis and the discovery of new potential therapeutic targets. Phase I and II clinical trials are already ongoing, with some promising results for these patients. This article reviews OS pathogenesis and new potential therapeutic targets.
摘要
骨肉瘤（OS）是一种罕见的疾病，在转移的情况下预后非常差。基础研究使我们能够更好地了解 OS 的发病机制，并发现新的潜在治疗靶点。目前已经开展了 I 期和 II 期临床试验，这些患者的一些结果很有前景。本文综述了 OS 的发病机制和新的潜在治疗靶点。
相似文献
1
Osteosarcoma Pathogenesis Leads the Way to New Target Treatments.成骨肉瘤发病机制为新靶点治疗开辟道路。
Int J Mol Sci. 2021 Jan 15;22(2):813. doi: 10.3390/ijms22020813.
2
Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas.胰岛素样生长因子 1 型受体（IGF-1R）特异性核染色：预测肉瘤中 IGF-1R 单克隆抗体（Ab）治疗的生物标志物。
Eur J Cancer. 2012 Nov;48(16):3027-35. doi: 10.1016/j.ejca.2012.05.009. Epub 2012 Jun 7.
3
The possible role of insulin-like growth factor-1 in osteosarcoma.胰岛素样生长因子-1 在骨肉瘤中的可能作用。
Curr Probl Cancer. 2019 Jun;43(3):228-235. doi: 10.1016/j.currproblcancer.2018.08.008. Epub 2018 Sep 7.
4
HER-2 involvement in osteosarcoma.HER-2 参与骨肉瘤。
Adv Exp Med Biol. 2014;804:161-77. doi: 10.1007/978-3-319-04843-7_9.
5
Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma.骨肉瘤分子靶向治疗的当前进展与未来展望
Int J Mol Sci. 2016 Apr 6;17(4):506. doi: 10.3390/ijms17040506.
6
Elimination of Osteosarcoma by Necroptosis with Graphene Oxide-Associated Anti-HER2 Antibodies.基于氧化石墨烯相关抗 HER2 抗体的细胞坏死疗法消除骨肉瘤。
Int J Mol Sci. 2019 Sep 5;20(18):4360. doi: 10.3390/ijms20184360.
7
Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma.HER2表达在骨肉瘤和尤文肉瘤中的预后及治疗相关性
Eur J Cancer. 2005 Jun;41(9):1349-61. doi: 10.1016/j.ejca.2005.03.015.
8
Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group.曲妥珠单抗联合细胞毒化疗治疗人表皮生长因子受体 2 过表达转移性骨肉瘤的 II 期临床试验：来自儿童肿瘤学组的报告。
J Clin Oncol. 2012 Jul 10;30(20):2545-51. doi: 10.1200/JCO.2011.37.4546. Epub 2012 Jun 4.
9
The novel synthesized 6-fluoro-(3-fluorophenyl)-4-(3-methoxyanilino)quinazoline (LJJ-10) compound exhibits anti-metastatic effects in human osteosarcoma U-2 OS cells through targeting insulin-like growth factor-I receptor.新型合成的 6-氟-(3-氟苯基)-4-(3-甲氧基苯胺基)喹唑啉（LJJ-10）化合物通过靶向胰岛素样生长因子-I 受体，在人骨肉瘤 U-2 OS 细胞中表现出抗转移作用。
Int J Oncol. 2011 Sep;39(3):611-9. doi: 10.3892/ijo.2011.1071. Epub 2011 Jun 8.
10
Advanced development of ErbB family-targeted therapies in osteosarcoma treatment.在骨肉瘤治疗中，针对 ErbB 家族的靶向治疗的深入发展。
Invest New Drugs. 2019 Feb;37(1):175-183. doi: 10.1007/s10637-018-0684-8. Epub 2018 Oct 24.
引用本文的文献
1
Systemic strategies for osteosarcoma: advances and future directions.骨肉瘤的全身治疗策略：进展与未来方向
Discov Oncol. 2025 Jul 18;16(1):1367. doi: 10.1007/s12672-025-02208-9.
2
Myeloid Cells in the Immunosuppressive Microenvironment as Immunotargets in Osteosarcoma.免疫抑制微环境中的髓样细胞作为骨肉瘤的免疫靶点
Immunotargets Ther. 2025 Mar 19;14:247-258. doi: 10.2147/ITT.S485672. eCollection 2025.
3
Thrombospondin 1 Promotes Cytoskeleton Remodeling, Dedifferentiation, and Pulmonary Metastasis through ITGA1 and ITGA6 in Osteosarcoma.血小板反应蛋白1通过整合素α1和整合素α6促进骨肉瘤的细胞骨架重塑、去分化和肺转移。
Int J Biol Sci. 2025 Feb 18;21(5):2083-2100. doi: 10.7150/ijbs.93678. eCollection 2025.
4
Osteosarcoma tumor microenvironment: the key for the successful development of biologically relevant 3D in vitro models.骨肉瘤肿瘤微环境：构建具有生物学相关性的体外3D模型并取得成功的关键因素。
In Vitro Model. 2022 Jan 18;1(1):5-27. doi: 10.1007/s44164-022-00008-x. eCollection 2022 Feb.
5
Development of dual aptamers-functionalized c-MET PROTAC degraders for targeted therapy of osteosarcoma.用于骨肉瘤靶向治疗的双适配体功能化c-MET PROTAC降解剂的开发
Theranostics. 2025 Jan 1;15(1):103-121. doi: 10.7150/thno.99588. eCollection 2025.
6
The efficacy and applicability of chimeric antigen receptor (CAR) T cell-based regimens for primary bone tumors: A comprehensive review of current evidence.嵌合抗原受体（CAR）T细胞疗法用于原发性骨肿瘤的疗效及适用性：当前证据的全面综述
J Bone Oncol. 2024 Sep 22;48:100635. doi: 10.1016/j.jbo.2024.100635. eCollection 2024 Oct.
7
Correlation of High-Grade Osteosarcoma Response to Chemotherapy with Enhanced Tissue Immunological Response: Analysis of CD95R, IFN-γ, Catalase, Hsp70, and VEGF.骨肉瘤对化疗高反应性与增强组织免疫反应的相关性：CD95R、IFN-γ、过氧化氢酶、Hsp70 和 VEGF 的分析。
Virchows Arch. 2024 Jun;484(6):925-937. doi: 10.1007/s00428-024-03801-z. Epub 2024 May 15.
8
Lipid Peroxidation-Related Redox Signaling in Osteosarcoma.骨肉瘤中与脂质过氧化相关的氧化还原信号传导
Int J Mol Sci. 2024 Apr 22;25(8):4559. doi: 10.3390/ijms25084559.
9
Targeting Intratibial Osteosarcoma Using Water-Soluble Copolymers Conjugated to Collagen Hybridizing Peptides.靶向富血小板纤维蛋白水凝胶联合间充质干细胞治疗兔激素性股骨头坏死
Mol Pharm. 2023 Mar 6;20(3):1670-1680. doi: 10.1021/acs.molpharmaceut.2c00880. Epub 2023 Feb 1.
10
Development and validation of a cuproptosis-related lncRNA model correlated to the cancer-associated fibroblasts enable the prediction prognosis of patients with osteosarcoma.与癌症相关成纤维细胞相关的铜死亡相关lncRNA模型的开发与验证可实现骨肉瘤患者预后的预测
J Bone Oncol. 2022 Dec 9;38:100463. doi: 10.1016/j.jbo.2022.100463. eCollection 2023 Feb.
本文引用的文献
1
Alantolactone inhibits proliferation, metastasis and promotes apoptosis of human osteosarcoma cells by suppressing Wnt/β-catenin and MAPKs signaling pathways.土木香内酯通过抑制Wnt/β-连环蛋白和丝裂原活化蛋白激酶（MAPKs）信号通路来抑制人骨肉瘤细胞的增殖、转移并促进其凋亡。
Genes Dis. 2020 Aug 8;9(2):466-478. doi: 10.1016/j.gendis.2020.07.014. eCollection 2022 Mar.
2
Role of microRNAs in the crosstalk between osteosarcoma cells and the tumour microenvironment.微小RNA在骨肉瘤细胞与肿瘤微环境之间相互作用中的作用
J Bone Oncol. 2020 Sep 28;25:100322. doi: 10.1016/j.jbo.2020.100322. eCollection 2020 Dec.
3
miR-429 inhibits osteosarcoma progression by targeting HOXA9 through suppressing Wnt/β-catenin signaling pathway.微小RNA-429通过抑制Wnt/β-连环蛋白信号通路靶向同源盒A9来抑制骨肉瘤进展。
Oncol Lett. 2020 Sep;20(3):2447-2455. doi: 10.3892/ol.2020.11766. Epub 2020 Jun 24.
4
Ginsenoside Rg3 Inhibits the Growth of Osteosarcoma and Attenuates Metastasis through the Wnt/-Catenin and EMT Signaling Pathway.人参皂苷Rg3通过Wnt/β-连环蛋白和上皮-间质转化信号通路抑制骨肉瘤生长并减弱其转移。
Evid Based Complement Alternat Med. 2020 Jul 11;2020:6065124. doi: 10.1155/2020/6065124. eCollection 2020.
5
Tumor-Associated Macrophages in Osteosarcoma: From Mechanisms to Therapy.骨肉瘤中的肿瘤相关巨噬细胞：从机制到治疗。
Int J Mol Sci. 2020 Jul 23;21(15):5207. doi: 10.3390/ijms21155207.
6
Epidemiology and Risk Factors of Osteosarcoma.骨肉瘤的流行病学和危险因素。
Cancer Invest. 2020 May;38(5):259-269. doi: 10.1080/07357907.2020.1768401. Epub 2020 Jun 1.
7
Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung.一项关于萨拉卡替尼（AZD0530）治疗局限于肺部的复发性骨肉瘤患者的随机、双盲、安慰剂对照2.5期研究结果
Sarcoma. 2020 Apr 30;2020:7935475. doi: 10.1155/2020/7935475. eCollection 2020.
8
The Osteosarcoma Microenvironment: A Complex But Targetable Ecosystem.成骨肉瘤微环境：一个复杂但可靶向的生态系统。
Cells. 2020 Apr 15;9(4):976. doi: 10.3390/cells9040976.
9
Immuno-genomic landscape of osteosarcoma.骨肉瘤的免疫-基因组图谱。
Nat Commun. 2020 Feb 21;11(1):1008. doi: 10.1038/s41467-020-14646-w.
10
The Role of Non-coding RNAs in Oncology.非编码 RNA 在肿瘤学中的作用。
Cell. 2019 Nov 14;179(5):1033-1055. doi: 10.1016/j.cell.2019.10.017.
Zotero 插件